Trial Profile
Study CRH103390: A 12 Week Flexible Dose Study of GW876008, Placebo and Active Control (Paroxetine) in the Treatment of Social Anxiety Disorder (SocAD)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2023
Price :
$35
*
At a glance
- Drugs Emicerfont (Primary) ; Paroxetine
- Indications Social phobia
- Focus Therapeutic Use
- Sponsors GSK
- 05 Feb 2008 Status changed from in progress to completed according to Neurocrine media release.
- 24 Nov 2006 New trial record.